CRISPR Therapeutics AG (CRSP)

In the past six months, CRISPR Therapeutics AG's stock price has been impacted by several events. The Q3 2025 earnings report showed an EPS surpassing estimates but revenue missing expectations. Positive data from the CTX-310 program generated investor interest. There have been insider sales totaling approximately $7.51 million. The stock experienced a 13.32% decrease over the past six months.

The demand for CRISPR Therapeutics AG's products and services is not subject to traditional seasonal fluctuations. Demand is primarily driven by medical need, clinical trial progress, regulatory approvals, and market access for its therapies.

CRISPR Therapeutics AG is a biotechnology company focused on developing gene-based medicines using its CRISPR/Cas9 platform. Its lead product candidate, CASGEVY, is an ex vivo CRISPR/Cas9 gene-edited cell therapy approved in some countries for treating transfusion-dependent beta-thalassemia and severe sickle cell disease. The company is also developing CAR T cell therapies like CTX112 and CTX131, in vivo gene editing programs such as CTX310 and CTX320, and CTX211 for Type 1 Diabetes.

CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with operations in the United States, including R&D facilities in Boston, Massachusetts, and San Francisco, California. It also has business offices in London, United Kingdom, and a manufacturing facility in Framingham, Massachusetts.

CRISPR Therapeutics AG has received positive recognition for its pioneering work in gene editing, including being named to TIME's 100 Most Influential Companies list in 2025. The company was recognized for its advancements beyond sickle cell disease and beta thalassemia into areas like cardiovascular and autoimmune diseases. No significant negative events affecting the company's brand reputation were found.

CRISPR Therapeutics AG has significant institutional ownership, with 618 institutional owners holding a total of 91,563,161 shares. Major institutional owners include ARK Investment Management LLC, BlackRock, Inc., and Vanguard Group Inc. Significant insider holdings are also notable, with Celgene Corp owning 8.98% of the company. Insiders collectively own approximately 32.19% of the stock.